Mike Benson
Disclosure: I am in full compliance with all ethics and other policies for Market Realist research analysts. I am not invested in securities that I cover on Market Realist.
More From Mike Benson
Performances of ETFs Investing in Cannabis Stocks in Week 48
Cannabis industry ETFs are designed for those who can’t hold many stocks but are interested in diversifying within the cannabis sector.
Performance of Cannabis Stocks in Week 48
In this article, we’ll discuss the performances of a few stocks from the cannabis industry (SEED) for the week that ended on November 30.
iAnthus Capital Holdings’ Valuation as of November 30
iAnthus Capital Holdings (ITHUF) is a leading company in the cannabis industry (SEED).
iAnthus’s MPX Bioceutical Deal Highlights
iAnthus Capital Holdings announced in October that it had entered into an acquisition agreement with MPX Bioceutical for the acquisition of MPX’s US assets.
Assessing Curaleaf Holdings’ Major Developments Year-to-Date
Curaleaf Holdings (LDVTF) has entered into a few agreements for the expansion of its presence, and it’s also achieved a few milestones this year.
Comparing Cannabis Stocks with ETFs’ Performance in Week 47
ETFs investing in cannabis stocks The chart below compares ETFs’ returns in the last week. Horizons Marijuana Life Sciences Index ETF (HMMJ) This ETF focuses on North American publicly listed life sciences companies with significant business in the cannabis industry. The fund has operated since April 2017, and its market capitalization is 785.9 million Canadian […]
Why Was MedMen’s Trading Halted?
MedMen stock has fallen ~29.6% in November. The stock fell 26.3% in the last five trading sessions to close at $3.52 on November 20.
Trulieve Surpassed Analysts’ Q3 Revenue Estimates
Trulieve reported revenues of $28.3 million during the third quarter of 2018 as compared to Wall Street analyst estimates of $26.6 million during the quarter.
Trulieve to Announce Q3 Earnings on November 19!
Trulieve Cannabis Corp (TCNNF) is a licensed medical cannabis company set to release its Q3 2018 earnings on November 19 at 10:00 AM ET.
Curaleaf Opens Medical Marijuana Dispensary in Tallahassee
On November 16, Curaleaf Holdings announced that the company opened Tallahassee’s largest medical marijuana dispensary.
MedMen’s Cannabis Factories
MedMen (MMNFF) has three cultivation and production factories in Florida, Nevada, and New York.
MedMen’s Must-Know Revenue Drivers
MedMen’s (MMNFF) reported revenues are generated from direct sales through its retail stores. The company has reported no material revenues from cultivation or production wholesale operations.
What to Expect from Cannabis Player Curaleaf’s Q3 Earnings
A look at Curaleaf Curaleaf Holdings (LDVTF) is one of the leading cannabis operators in the United States. Curaleaf Holdings has announced that it will release its third-quarter earnings results on November 26. We’ll discuss analysts’ estimates for its EPS and revenue in this article. The chart above compares Curaleaf Holdings’ revenues since the third […]
Analyzing 22nd Century Group’s Year-to-Date Performance
Analysts expect 22nd Century Group to report revenue of $23.3 million in 2018, a 40.3% rise compared to $16.6 million in 2017.
A Closer Look at Insys Therapeutics’ Performance Year-to-Date
Insys Therapeutics (INSY) is among the specialty pharmaceutical companies that focus on developing cannabinoids and sprays.
How Marijuana-Focused Biotech Companies Have Performed in 2018
In this series, we’ll discuss analysts’ estimates, recommendations, and revenue estimates for marijuana biotechnology companies.
Allergan Beats EPS and Revenue Estimates: Q3 2018 Earnings
Allergan (AGN) released its Q3 2018 earnings today. The company beat Wall Street analysts’ estimates for EPS and revenues, and it reported non-GAAP EPS of $4.25 on revenues of $3.91 billion.
Sanofi: Analysts’ Recommendations on October 30
As of October 30, four analysts are tracking Sanofi. Two analysts recommend a “strong buy,” while two analysts recommend a “hold.”
Recommendations for Shire as of October 30
Analysts’ estimates show that Shire (SHPG) stock has a potential to return ~15.8% over the next 12 months.
Shire: Why Analysts Expect Revenue Growth in Q3 2018
Analysts are expecting Shire (SHPG) to report a 3.3% growth in revenue when it reports its third-quarter earnings on November 1.
GlaxoSmithKline’s Q3 2018 Earnings: Analysts’ Estimates
Analysts are expecting GlaxoSmithKline’s revenues to increase 2.3% to 8.02 billion pounds for the third quarter of 2018.
Analysts Expect Incyte to Report Revenue Growth in Third Quarter
Analysts estimate Incyte (INCY) to report growth of 17.7% in its revenues to $449.2 million during the third quarter of 2018.
Amgen: Analysts’ Recommendations on October 25
Wall Street analysts expect Amgen’s (AMGN) revenues to decrease marginally by ~0.1% to $5.769 billion during the third quarter.
Amgen: Expect Nearly Flat Revenues in Q3
New products are expected to deliver double-digit growth, while legacy brands are expected to offset the growth during the quarter.
Thermo Fisher Beats Analysts’ Estimates in Q3 2018 Earnings
Thermo Fisher Scientific (TMO) reported its third-quarter results today. It surpassed analysts’ estimates for EPS and revenue.
Allergan’s Q3 2018 Estimates: Revenue Decline Expected
Analysts are estimating that Allergan’s (AGN) third-quarter revenues will decline 3.8% to $3.88 billion.
Allergan’s Q3 2018 Earnings: Analysts’ Estimates
Allergan (AGN) is set to release its Q3 2018 earnings on October 30. Analysts estimate EPS of $4.03 on revenues of $3.88 billion.
Biogen Surpassed Estimates in Q3 2018, Reports Strong Growth
Today, Biogen (BIIB) reported EPS of $7.40 on revenues of ~$3.44 billion. BIIB beat the EPS estimate of $6.78 on revenues of ~$3.33 billion.
Pfizer: Analysts Expect Revenue Growth in Q3
Analysts expect Pfizer’s (PFE) revenues to be ~$13.5 billion in the third quarter—which is ~2.8% growth compared to the third quarter of 2017.
How Novartis’s Sandoz Performed in the Third Quarter
Novartis’s (NVS) Sandoz is a market leader in differentiated generics.
Biogen: Analysts’ Recommendations on October 19
For Biogen, eight analysts recommended a “strong buy,” 12 recommended a “buy,” and nine recommended a “hold.”
Biogen: Revenue Growth Is Expected in Q3
Interferon contributed ~18% of Biogen’s total revenues. Analysts expect the revenues to decrease during the third quarter.
Thermo Fisher’s Third-Quarter Revenue Estimates
The Life Sciences Solutions segment, including reagents, instruments, and consumables, contributes ~25% of Thermo Fisher’s total revenues.
What to Expect from Thermo Fisher’s Third-Quarter Earnings
Thermo Fisher Scientific (TMO), a leading life sciences company, is scheduled to release its third-quarter earnings on October 24.
Novartis Missed Revenue Estimates in Q3 2018
Novartis released its third-quarter earnings results on October 18. Let’s see how it performed compared to analysts’ consensus estimates.
What’s Pfizer’s Current Valuation?
Pfizer is trading at a forward PE ratio of ~14.5x on October 18—compared to the industry average of ~15.7x.
Pfizer’s Dividends and Earnings Quality
Pfizer’s dividend yield is 3.15%. The company’s historical dividend yield was 3.53% in 2017, while the five-year average yield is 3.44%.
Pfizer’s Growth Rate and Estimates
Pfizer (PFE) reported an EPS of $0.74 on revenues of ~$13.5 billion during the second quarter, which beat analysts’ estimate of ~$13.3 billion.
What Are Pfizer’s Revenue Drivers?
Pfizer reported revenues of $13.5 billion during the second quarter—4% growth YoY compared to $12.9 million during the second quarter of 2017.
Pfizer’s Market Cap and Shareholding Pattern
Pfizer’s total shares outstanding are ~5.862 billion. There are ~5.859 billion free-floating shares—nearly 99.95% of the total outstanding shares.
Analyzing Pfizer’s Stock Performance in October
Pfizer (PFE) is one of the leading healthcare companies. Pfizer stock increased 1.5% and closed at $44.57 on October 17.
Novartis in Q3 2018: Analysts Expect Revenue Growth
Analysts expect Novartis’s revenues to increase ~4.9% to $13.02 billion in the third quarter of 2018.
A Look at the Performance of Novartis’s Alcon
Alcon reported revenue of ~$1.82 billion in the second quarter, a 7% rise.
How Novartis’s Sandoz Business Has Been Performing Recently
Sandoz, Novartis’s (NVS) generics business, is a market leader in differentiated generics.
A Closer Look at Novartis’s Innovative Medicines Segment
Novartis’s Innovative Medicines segment includes prescription products from two business units: Novartis Pharmaceuticals and Novartis Oncology.
A Look at Novartis’s Valuation on October 9
Novartis AG (NVS) reported EPS of $1.29 on revenue of $13.2 billion in the second quarter, reporting a 7% YoY (year-over-year) rise in revenue.
Insys Therapeutics: Recommendations and Market Capitalization
Wall Street analysts estimate that INSY stock could decrease ~3% over the next 12 months. That show a 12-month target price of $9.60.
Cara Therapeutics: Performance and Estimates for Q3
Cara Therapeutics reported revenues of $2.87 million in the second quarter compared to no revenues in the second quarter of 2017.
GW Pharmaceuticals: Recommendations and Market Capitalization
Wall Street analysts estimate that GWPH stock could increase ~6.7% over the next 12 months.
Marijuana-Focused Biotech Companies in Q3: Are They Performing?
In this series, we’ll look at biotechnology companies focused on marijuana-based products and how they performed in the third quarter.
Novartis ADR’s Performance and Revenue Estimates for Q3 2018
Novartis’s (NVS) stock price has increased ~14.3% in the third quarter, and its stock rose ~2.8% year-to-date on October 2.
GlaxoSmithKline ADR’s Performance and Revenues in Q3 2018
Five analysts are currently tracking GlaxoSmithKline ADR. One analyst recommends a “strong buy,” and four analysts recommend a “hold.”
Amgen’s Stock Performance and Estimates after Q3 2018
Analysts expect Amgen’s (AMGN) stock price to fall ~1.4% over the next 12 months.
Allergan’s Stock Performance and Estimates for Q3 2018
Wall Street analysts expect Allergan to report EPS of $3.98 on revenues of $3.8 billion in the third quarter.
How Did Pfizer Stock Fare in Q3 2018?
Nineteen analysts currently track Pfizer stock. The consensus rating for Pfizer stands at 2.63, which represents a “hold.”
Eli Lilly’s Stock Performance and Estimates for Q3 2018
Sixteen analysts currently track Eli Lilly (LLY) stock. Two analysts recommend a “strong buy,” six analysts recommend a “buy,” and eight analysts recommend a “hold.”
How Did Pharmaceutical ETFs Perform in Q3 2018?
The Healthcare Select Sector SPDR ETF’s (XLV) price has increased ~14.6% in the third quarter, and its year-to-date returns increased ~15.5% on October 2.
Mergers and Acquisitions in the Pharmaceuticals Sector in Q3 2018
On October 2, Johnson & Johnson announced the completion of the divestiture of its LifeScan business to Platinum Equity for ~$2.1 billion.
Ionis Pharmaceuticals’ Revenue Stream
Ionis’s Commercial Revenues segment reported second-quarter revenues of $57.0 million, compared to $24.0 million during the second quarter of 2017.
Ionis Pharmaceuticals’ Revenue Growth Rate
Ionis Pharmaceuticals (IONS) reported revenues of $262.0 million during the first half of 2018.
Ionis Pharmaceuticals’ Valuations on September 28
Ionis reported revenues of $118.0 million during the second quarter for 5.0% growth in year-over-year revenues compared to the second quarter of 2017.
Ionis Pharmaceuticals’ Stock Performance in September
On September 28, Ionis Pharmaceuticals received one “strong buy” rating, three “buy” ratings, seven “hold” ratings, and two “sell” ratings.
How GlaxoSmithKline’s Pharmaceutical Business Performed
GlaxoSmithKline’s (GSK) Pharmaceutical segment includes various products from different therapeutic areas including respiratory products, HIV products, immuno-inflammation products, and established products.
GlaxoSmithKline’s Revenue Was Flat in Second Quarter
GlaxoSmithKline (GSK) reported revenues of 7.3 billion pounds during the second quarter of 2018.
How GlaxoSmithKline Stock Has Performed in September
Analyst estimates suggest GlaxoSmithKline stock could rise ~6.3% over the next 12 months.
A Look at Elanco, Eli Lilly’s Animal Health Business
Eli Lilly’s Elanco reported a 1% YoY (year-over-year) rise in revenue to $792.1 million in the second quarter.
Eli Lilly’s Earnings Quality and Dividend Performance
Eli Lilly’s dividend yield is 2.11%. Its dividend yield last year was 2.46%, and its five-year average is 2.77%.
Eli Lilly’s Market Cap and Shareholding Pattern
Eli Lilly and Company’s (LLY) market cap is ~$106.0 billion as of September 26.
What’s Eli Lilly’s Valuation as of September 27?
Eli Lilly and Company (LLY) reported a top line of $6.4 billion in the second quarter, a 9% YoY (year-over-year) rise in revenue.
Eli Lilly’s Stock Performance in September
Eli Lilly stock reported a ~0.6% rise to close at $106.31 on September 26 compared to the previous day’s close.
Comparing Pfizer Stock and Eli Lilly Stock
Eli Lilly and Company (LLY) stock has fallen a marginal ~0.1% so far in September, and its closing price was $105.59 on September 24.
Comparing Pfizer Stock and Merck and Co. Stock
Merck & Co. (MRK) stock has risen ~3.2% in the same period, with a closing price of $70.78 on September 24.
Pfizer’s Earnings Quality and Dividend Performance
Pfizer’s dividend yield is 3.09%. Its dividend yield last year was 3.53%, and its five-year average yield is 3.44%.
A Look at Pfizer’s Market Cap and Shareholding Pattern
The total number of Pfizer’s outstanding shares is ~5.862 billion. Of these, its free-floating shares total ~5.859 billion.
Assessing Pfizer’s Global Performance
Pfizer reported a rise in revenue in international markets in the second quarter, though this growth was offset by lower sales in US markets.
Pfizer’s Revenue and EPS Growth Rate
Pfizer (PFE) reported EPS of $0.74 on revenue of ~$13.5 billion in the second quarter, surpassing Wall Street analysts’ consensus estimate.
Allergan’s SpotLyte and Lumivive System
SpotLyte is the first venture from Project Moonwalker and is designed to educate consumers on medical aesthetics.
A Closer Look at the Allergan–Bonti Deal
On September 14, Allergan (AGN) announced the acquisition of Bonti Inc., a clinical-stage biotechnology company.
Allergan’s First Medical Aesthetics Innovation Center in China
Allergan’s total investment in the Medical Aesthetics and Innovation Center is ~$14.7 million.
Allergan’s Developments in September
On September 20, Allergan (AGN) announced a partnership with actor Scott Eastwood to encourage the recognition of World Alzheimer’s Day on September 21.
Allergan’s Stock Price Performance in September
On September 21, 23 analysts tracked Allergan (AGN) stock. Four analysts recommended a “strong buy,” and 12 analysts recommended a “buy.”
Here Are the Key Products in Sage’s GABA Receptor Portfolio
Sage Therapeutics’ (SAGE) portfolio includes products under development for the treatment of life-threatening central nervous system (or CNS) disorders.
A Look at Sage Therapeutics’ NMDA Receptor Portfolio
Sage Therapeutics (SAGE) is focused on the development of products for the treatment of life-threatening central nervous system (or CNS) disorders.
How Does Sage Therapeutics’ Product Portfolio Look in September?
Sage Therapeutics’ (SAGE) product portfolio includes products under development for the treatment of various rare and life-threatening central nervous system disorders.
Shire’s Quarterly Revenue Trend
Biotechnology company Shire (SHPG) reported a 4.6% YoY (year-over-year) rise in revenue to ~$3.9 billion in the second quarter.
Estimates and Recommendations for Shire on September 19
Wall Street analysts expect Shire (SHPG) to report a 2.7% rise in revenue to ~$15.56 billion in 2018 compared to ~$15.16 billion in 2017.
A Look at Shire’s Valuation on September 19
Shire reported adjusted EPS of $3.88 on revenue of ~$3.9 billion in the second quarter, a 4.6% YoY (year-over-year) rise.
Pharma Stocks: Allergan’s Revenue Trend and 2018 Estimates
Allergan (AGN) reported revenue of $4.1 billion in the second quarter, a 2.9% YoY (year-over-year) rise in revenue.
Pharma Stocks: Merck & Co.’s Revenue Trend and 2018 Estimates
Merck & Co. (MRK) reported revenue of ~$10.5 billion in the second quarter, a 5% YoY (year-over-year) rise in revenue.
Pharma Stocks: Pfizer’s Revenue Trend and 2018 Estimates
Pfizer (PFE) reported revenue of ~$13.5 billion in the second quarter, a 4% YoY (year-over-year) rise in revenue.
Pharma Stocks in Review: A Valuation Comparison
In this article, we’ll compare the valuations of Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).
A Review of Pharma Stocks’ EPS Growth Rates
In this article, we’ll compare the EPS growth rates of Eli Lilly (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).
Exploring Pharmaceutical Stocks’ Revenue Growth Rates
In this article, we’ll compare the revenue growth rates of the pharmaceutical companies under review in this series.
A Look at the Dividends Paid by Pharma Stocks in 2018
In this article, we’ll discuss the details of the dividends paid by the pharmaceutical stocks under review in this series.
How Pharmaceutical ETFs Have Performed in 2018
The SPDR S&P Pharmaceuticals ETF holds ~5.0% of its total investments in Eli Lilly and Company (LLY).
These Pharmaceutical Stocks Have Surpassed the S&P 500 in 2018
Pharmaceutical stocks that have surpassed the S&P 500 Index’s returns YTD include Eli Lilly, Pfizer, Merck, Allergan, and GlaxoSmithKline.
Estimates and Recommendations for DaVita on September 17
Analysts estimate that DaVita (DVA) will report a 25.3% decline in revenues to $11.6 billion in 2018 compared to $15.5 billion in 2017.
DaVita’s Valuation on September 17
DaVita currently trades at a forward PE multiple of 15.2x compared to the industry average of 15.1x as of September 17.
Allergan Unveils Spotlyte, Its First Digital Ventures Launch
On September 12, Allergan (AGN) announced the launch of Spotlyte, the first launch from Project Moonwalker, the Allergan-owned digital ventures unit.
Thermo Fisher to Acquire BDX’s Advanced Bioprocessing Business
Thermo Fisher Scientific (TMO) announced on September 7, 2018, that the company would acquire the Advanced Bioprocessing Business from Becton Dickinson (BDX).